PROGRESS-AD Efficacy and safety of GSK4527226 in participants with early Alzheimer's disease Sponsor GlaxoSmithKline Clinical Trial Phase II Status Ongoing studies but not recruiting Drug GSK4527226
ASPIRE-FTD A study to evaluate the safety and effect of AVB-101, a gene therapy product, in subjects with a genetic sub-type of frontotemporal dementia Frontotemporal dementia Sponsor AviadoBio Ltd Clinical Trial Phase II Status Currently recruiting Drug AVB-101
AUTONOMY A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Mild Alzheimer's dementia Sponsor Janssen Research & Development Clinical Trial Phase II Status Ongoing studies but not recruiting Drug JNJ-63733657
CELIA A randomised, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of BIIB080 in subjects with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Mild Alzheimer's dementia Sponsor Biogen Clinical Trial Phase II Status Ongoing studies but not recruiting Drug BIIB080
DIAN-TU Dominantly Inherited Alzheimer Network Trial: An opportunity to prevent dementia. A study of potential disease modifying treatments in individuals with a type of early onset Alzheimer's disease caused by a genetic mutation At risk of developing Alzheimer’s dementia or family history of Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Sponsor Washington University School of Medicine Clinical Trial Phase III Status Ongoing studies but not recruiting Drug Lecanemab & E2814
DIAN-TU-001 A study of potential disease modifying treatments in individuals at risk for or with a type of early onset Alzheimer’s disease caused by a genetic mutation (DIAN-TU) At risk of developing Alzheimer’s dementia or family history of Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Sponsor Washington University School of Medicine Clinical Trial Phase III Status Ongoing studies but not recruiting Drug Lecanemab & E2814
DNLI-H-0001 A study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of DNL593 in healthy participants and participants with Frontotemporal Dementia (FTD-GRN) Sponsor Denali Therapeutics Inc. Clinical Trial Phase II Status Ongoing studies but not recruiting Drug DNL593
evoke evoke - A research study investigating Semaglutide in people with early Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Mild Alzheimer's dementia Sponsor Novo Nordisk A/S Clinical Trial Phase III Status Ongoing studies but not recruiting Drug Semaglutide
evoke+ evoke+ - A research study investigating Semaglutide in people with early Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Mild Alzheimer's dementia Sponsor Novo Nordisk A/S Clinical Trial Phase III Status Ongoing studies but not recruiting Drug Semaglutide
FINGER-NL Dutch Multidomain Lifestyle Intervention in Older Adults at Risk of Cognitive Decline At risk of developing Alzheimer’s dementia or family history of Alzheimer's disease Sponsor Alzheimer Center Amsterdam & Maastricht University Clinical Trial Lifestyle behaviour & intervention Status Ongoing studies but not recruiting Drug Multidomain lifestyle intervention
INFRONT-3 A Phase 3 study to evaluate efficacy and safety of AL001 in frontotemporal dementia Frontotemporal dementia Sponsor Alector Inc. Clinical Trial Phase III Status Ongoing studies but not recruiting Drug AL001
LIGHT study Lifestyle Intervention in the memory clinics of General and academic Hospitals Trial Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Sponsor Maastricht University Clinical Trial Lifestyle behaviour & intervention Status Currently recruiting Drug Personalised lifestyle intervention
MINDSET 2 A study to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's disease Mild Alzheimer's dementia Moderate Alzheimer’s dementia Sponsor Bristol-Myers Squibb Clinical Trial Phase III Status Currently recruiting Drug KarXT + KarX-EC
MK-1167-008 A study to evaluate the efficacy and safety of MK-1167 in participants with Alzheimer's disease dementia Mild Alzheimer's dementia Moderate Alzheimer’s dementia Sponsor Merck Sharp & Dohme LLC Clinical Trial Phase II Status Currently recruiting Drug MK-1167
MK-2214-004 A clinical study of MK-2214 in people with early Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Mild Alzheimer's dementia Sponsor Merck Sharp & Dohme LLC Clinical Trial Phase II Status Currently recruiting Drug MK-2214
POLARIS-AD Phase 3, double-blind, randomised, placebo-controlled trial to evaluate the efficacy and safety of AR1001 in participants with early Alzheimer's disease Sponsor AriBio Co Clinical Trial Phase III Status Ongoing studies but not recruiting Drug AR1001
PRImus-AD Study to assess safety and efficacy of PRI-002 in patients with Mild Cognitive Impairment (MCI) to mild dementia due to Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Mild Alzheimer's dementia Sponsor PRInnovation GmbH Clinical Trial Phase II Status Ongoing studies but not recruiting Drug PRI-002
Stichting Alzheimer Indonesia Nederland (NL) The website (https://alzined.org/) contains information on events and information flyers developed together with people from the minority ethnic groups concerned Target Audience People with Dementia Informal Carers Communities Indonesian Available languages Indonesian English Initiative Type Website
TRAILBLAZER-ALZ 2 A Study of Donanemab (LY3002813) in participants with early Alzheimer's disease Prodromal/Mild Cognitive Impairment due to Alzheimer’s disease Mild Alzheimer's dementia Sponsor Eli Lilly and Company Clinical Trial Phase III Status Ongoing studies but not recruiting Drug Donanemab
